Company | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Aradigm | Private placement of Series A convertible preferred stock | 2S | $48.4 | Aradigm raised $48.4M through the sale of 2M shares; investors were led by New Enterprise Associates, and included Camden Partners Inc., Castle Creek Partners and Domain Public Equity Partners (12/13) |
| ||||
Axonyx Inc. | Private placement of common stock and warrants | W for 0.98S | $6.4 | Axonyx raised $6.4M through the sale of common stock and warrants to a group of accredited investors; the stock was purchased at $3.26 per share; buyers also received two-year warrants to purchase an additional 985,000 shares at $3.91 per share (12/6) |
| ||||
Bioject | Private placement of common stock | 0.35S | $3.85 | Bioject raised $3.85M in a private placement; Leerink, Swann & Co. acted as placement agent (12/20) |
| ||||
Cephalon | Private placement of convertible notes | ND | $500 | Cephalon placed $500M of 2.5% notes; the agreement was managed by Credit Suisse First Boston (12/6) |
| ||||
Columbia | Private placement of common stock | 1.12S | $2.97 | Columbia raised $2.97M through a private sale of 1.12M shares; Acqua Wellington, Curran Partners and John Curran Affiliates, EGS Partners, Hillhouse Capital, Irvine Capital and Knott Partners participated in the financing (12/12) |
| ||||
ConjuChem | Private placement of a convertible note | ND | C$30 (US$19) | ConjuChem entered into an agreement with Baker/Tisch Capital, securing US$19M of financing via a convertible note (12/7) |
| ||||
Corixa Corp. | Equity line of credit | ND |
| Corixa secured a $75M equity line of credit with BNY Capital Markets Inc. (12/5) |
| ||||
Cubist Pharm- | Private placement of convertible subordinated notes | ND | $40 | Cubist raised another $40M when purchasers of $125M in notes in October exercised their option for additional notes, bringing the total raised to $165M (12/26) |
| ||||
EntreMed | Private placement of common stock and warrants | 2.9S and W for 0.73S | $22.6 | EntreMed raised $22.6M in a private placement (12/19) |
| ||||
Epimmune | Private placement of common stock | 2S | $5 | Epimmune raised $5M with the placement of 2M shares; investors included the State of Wisconsin Investment Board, International Biotechnology Trust, Genencor International Inc., Peter Allard and Ted Greene (12/19) |
| ||||
GenVec Inc. | Private placement of common stock | 3.6S | $13 | GenVec raised $13M by placing about 3.6M shares to funds managed by HealthCare Ventures (12/26) |
| ||||
GlycoGenesys | Private placement of common stock | 4.2S and W | $5.3 | GlycoGenesys raised $5.3M in net proceeds from institutional and accredited investors (12/21) |
| ||||
Heska Corp. | Private placement of common stock | 7.8S | $6 | Heska raised $6M in a private placement; investors were led by the State of Wisconsin Investment Board (12/20) |
| ||||
Hollis-Eden | Private placement of common stock and warrants | 1.3S and W for 0.13S | $11.5 | Hollis-Eden raised $11.5M through the sale of about 1.3M shares at $9 per share and warrants to purchase up to 128,000 shares of common stock (12/13) |
| ||||
IGEN Inter- | Private placement of common stock | 1.02S | $30 | IGEN completed a $30M private placement of 1.02M shares to Acqua Wellington Private Placement Fund Ltd. and Acqua Wellington Opportunity I Ltd. (12/12) |
| ||||
Interneuron | Private placement of common stock | 3.125S | $25 | Interneuron raised $25M by placing 3.125M shares to institutional investors; Legg Mason Wood Walker acted as placement agent |
| ||||
Invitrogen | Private placement of convertible subordinated notes | ND | $500 | Invitrogen sold $500M in notes in a private placement (12/6) |
| ||||
Martek | Private placement of common stock | 1.2S | $22.5 | Martek placed about 1.2M shares at $19.25 each; Adams, Harkness & Hill served as placement agent (12/18) |
| ||||
NeoThera- | Private placement of common stock | 0.77S | $2.95 | NeoTherapeutics placed 0.77M shares, raising $2.95M; Ladenburg Thalmann & Co. Inc. and Cantor Fitzgerald & Co. served as placement agents (12/12) |
| ||||
Orphan | Private placement of common stock | 1.7S | $14.1 | Orphan Medical raised $14.1M in a private placement of 1.7M shares to Alta Bio Pharma Partners LP; funds were managed by current investors OrbiMed Advisors LLC and Medical Strategy; Thomas Weisel Partners LLC acted as Orphan's agent and financial adviser in the transaction (12/10) |
| ||||
Ribozyme | Private placement of common stock and warrants | 0.75S and W for 0.075S | $3 | Ribozyme received an additional $3M in its private placement begun in November, bringing the total raised to $12.5M; ABN AMRO Inc. served as financial adviser and placement agent (12/28) |
| ||||
Senesco | Private placement of common stock and warrants | 1.1S and W for 1S | $2 | Senesco completed a $2M placement with Stanford Venture Capital Holdings Inc. (12/5) |
| ||||
Sepracor | Private placement of convertible subordinated notes | ND | $100 | Sepracor raised another $100M in a private placement conducted in November; the initial purchaser exercised in full the $100M overallotment option (12/21) |
| ||||
Visible | Private placement of common stock | 2.6S | $22 | Visible Genetics raised $22M in a private placement (12/26) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
@ Dates refer to the date of the press release. |
||||
N/A = Not available, applicable or reported. |
||||
AMEX = American Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |